1. Herzog CA, Natwick T, Li S, Charytan DM. Comparative utilization and temporal trends in cardiac stress testing in U.S. medicare beneficiaries with and without chronic kidney disease. JACC Cardiovasc Imaging. 2019 Aug 1;12(8 Pt 1):1420–6.
2. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American heart association and the American college of cardiology foundation. J Am Coll Cardiol. 2012 Jul 31;60(5):434–80.
3. Doukky R, Fughhi I, Campagnoli T, Wassouf M, Ali A. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 Feb;24(1):112–8.
4. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol. 2003;14(2):431–9.
5. Kolkailah AA, Iskander M, Iskander F, Patel PP, Khan R, Doukky R. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: the largest cohort to date. J Nucl Cardiol. 2020 Jul 6.